Suppr
超能文献

Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

作者信息

Stroncek David, McCullough Jeffrey

出版信息

Expert Rev Hematol. 2012 Feb;5(1):1-3. doi: 10.1586/ehm.11.78.

DOI:10.1586/ehm.11.78

PMID:22272697

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3418668/

Abstract

摘要

相似文献

Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

Expert Rev Hematol. 2012 Feb;5(1):1-3. doi: 10.1586/ehm.11.78.

Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association.

Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103. doi: 10.1016/j.bbmt.2015.08.017. Epub 2015 Aug 22.

Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application.

Sci Rep. 2016 Feb 23;6:21757. doi: 10.1038/srep21757.

Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT).

Bone Marrow Transplant. 2013 Feb;48(2):220-5. doi: 10.1038/bmt.2012.119. Epub 2012 Jul 9.

Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.

Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):63-71. doi: 10.1007/s00005-016-0438-2. Epub 2016 Dec 8.

When selecting an HLA mismatched stem cell donor consider donor immune status.

Curr Opin Immunol. 2009 Oct;21(5):538-43. doi: 10.1016/j.coi.2009.07.016. Epub 2009 Sep 6.

Facilitating the ethical sourcing of donor hematopoietic stem cells for cell and gene therapy research and development.

Regen Med. 2024 Jun 2;19(6):317-326. doi: 10.1080/17460751.2024.2357930. Epub 2024 Jun 18.

Targeted recruitment of male donors for allogeneic haematopoietic cell transplantation: A review of the evidence.

Vox Sang. 2018 May;113(4):307-316. doi: 10.1111/vox.12632. Epub 2018 Jan 22.

How to select the best available related or unrelated donor of hematopoietic stem cells?

Haematologica. 2016 Jun;101(6):680-7. doi: 10.3324/haematol.2015.141119. Epub 2016 May 31.

[The methods used to collect hematopoietic stem cells].

Transfus Clin Biol. 2011 Apr;18(2):230-4. doi: 10.1016/j.tracli.2011.01.003. Epub 2011 Mar 11.

引用本文的文献

Hematopoietic Stem Cell Donors' Experiences of Information and Side-Effects During the First Year After Donation-A Swedish National Study.

J Clin Apher. 2025 Aug;40(4):e70050. doi: 10.1002/jca.70050.

Comparison between peripheral blood progenitor cell collection on the 4 or 5 day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.

Blood Transfus. 2023 Jan;21(1):37-41. doi: 10.2450/2022.0026-22. Epub 2022 Aug 9.

Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.

Front Oncol. 2020 Apr 15;10:541. doi: 10.3389/fonc.2020.00541. eCollection 2020.

We have a specific duty to maximise the safety of related donors.

Blood Transfus. 2012 Oct;10(4):407-10. doi: 10.2450/2012.0042-12. Epub 2012 Jul 12.

本文引用的文献

Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.

Transfusion. 2012 Mar;52(3):537-41. doi: 10.1111/j.1537-2995.2011.03313.x. Epub 2011 Aug 29.

Novel agents and approaches for stem cell mobilization in normal donors and patients.

Bone Marrow Transplant. 2012 Sep;47(9):1154-63. doi: 10.1038/bmt.2011.170. Epub 2011 Aug 29.

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

Haematologica. 2011 Jul;96(7):942-7. doi: 10.3324/haematol.2011.045740.

Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors.

Blood. 2011 Sep 1;118(9):2602-8. doi: 10.1182/blood-2011-04-348508. Epub 2011 Jun 30.

Congenital neutropenia: diagnosis, molecular bases and patient management.

Orphanet J Rare Dis. 2011 May 19;6:26. doi: 10.1186/1750-1172-6-26.

Plerixafor for autologous CD34 cell mobilization.

Core Evid. 2011;6:23-9. doi: 10.2147/CE.S7801. Epub 2011 Feb 8.

Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States.

Blood. 2010 Jun 17;115(24):5097-101. doi: 10.1182/blood-2010-01-262915. Epub 2010 Mar 12.

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Blood. 2009 Apr 9;113(15):3604-11. doi: 10.1182/blood-2008-08-175323. Epub 2009 Feb 3.

The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation.

Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S3-S5. doi: 10.1038/bmt.2008.102.

Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program.

Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):29-36. doi: 10.1016/j.bbmt.2008.05.018.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译